How to take Cavinton - composition, form of release, indications, side effects, analogues and price. Cavinton, solution for injection Cavinton medicine indications

Instructions for medical use

medicinal product

Cavinton®

Tradename

Cavinton®

International non-proprietary name

Vinpocetine

Dosage form

Solution for injection 10 mg/2 ml

Compound

2 ml of solution contains

active substance- vinpocetine 10 mg,

Excipients: ascorbic acid, sodium metabisulphite, tartaric acid, benzyl alcohol, sorbitol, water for injection.

Description

Colorless or slightly greenish clear solution

Pharmacotherapeutic group

Psychoanaleptics. Psychostimulants and nootropics. Psychostimulants and nootropics others. Vinpocetine

ATX code N06BX18

Pharmacological properties

Pharmacokinetics

When administered intravenously in the process of metabolism of the primary passage through the liver, 25-30% of vinpocetine is converted into apo-vincamic acid (AVA). Diseases of the liver and kidneys do not affect the metabolism of vinpocetine. Binding to blood proteins is 66%. The volume of distribution is 246.7 ± 88.5 l, which indicates a good distribution in the tissues. The clearance value of vinpocetine (66.7 l / h) exceeds the values ​​​​in plasma and in the liver (50 l / h), which indicates extrahepatic metabolism of the compound.

It penetrates well into various tissues and body fluids, including cerebrospinal fluid. The half-life is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the gastrointestinal tract. Removal of apovincamic acid is carried out by glomerular filtration. The half-life depends on the dose of vinpocetine and the dosing regimen.

Elderly age: there are no significant differences in the kinetics of the drug in elderly and young patients, the drug does not accumulate. For patients with chronic diseases of the liver and kidneys, the drug is prescribed in the usual dose, the absence of cumulation allows for long courses of treatment.

Pharmacodynamics

Vinpocetine is a compound with a complex mechanism of action that has a beneficial effect on brain metabolism and improves its blood supply, as well as improves blood rheology.

The neuroprotective effect of vinpocetine is associated with the blockade of voltage-dependent Na + and Ca 2+ tubules and the protection of neurons from inadequate influx of Na + under conditions of hypoxia and the excessive Ca 2+ entry into the cell caused by it. The interaction of vinpocetine with glutamate receptors protects nerve cells from the cytotoxic effects of glutamate and N-methyl-D-aspartate, as well as alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid.

Vinpocetine enhances the neuroprotective effect of adenosine by blocking its utilization. It has a direct antioxidant effect, preventing the formation of reactive substances.

Vinpocetine stimulates cerebral metabolism: the drug increases the uptake of glucose and oxygen, increasing the consumption of these substances by the brain tissue. The drug increases the resistance of the brain to hypoxia; increases the transport of glucose - an exclusive source of energy for the brain - through the blood-brain barrier; shifts glucose metabolism towards an energetically more favorable aerobic pathway; selectively inhibits Ca 2+ -calmodulin-dependent enzyme cGMP-phosphodiesterase (PDE); increases the levels of cAMP and cGMP in the brain. The drug increases the concentration of ATP and the ratio of ATP / AMP; enhances the turnover of norepinephrine and serotonin in the brain; stimulates the ascending noradrenergic system; has antioxidant activity; as a result of all the above effects, vinpocetine has a cerebroprotective effect.

Vinpocetine improves microcirculation in the brain: the drug inhibits platelet aggregation; reduces pathologically increased blood viscosity; increases the deformability of erythrocytes and inhibits the capture of adenosine; improves the transport of O 2 in tissues by reducing the affinity of O 2 to erythrocytes.

Vinpocetine selectively increases blood flow in the brain: the drug increases the cerebral fraction of cardiac output; reduces vascular resistance in the brain without affecting systemic circulation parameters (blood pressure, cardiac output, pulse rate, total peripheral resistance); the drug does not cause a “steal effect”. Moreover, the drug improves blood flow to damaged (but not yet necrotic) ischemic areas with low perfusion (“reverse steal effect”).

As a result of such a complex mechanism of action, Vinpocetine accelerates the regression of cerebral and focal symptoms, improves memory, attention, and intellectual productivity.

Indications for use

transient cerebral ischemia

Cerebral ischemic stroke

Conditions after cerebral stroke

Dementia due to multiple brain lesions

Atherosclerosis of cerebral vessels

Post-traumatic and hypertensive encephalopathy

Vertebrobasilar insufficiency

Mental and neurological disorders caused by cerebrovascular insufficiency

Ophthalmic diseases of the retina and choroid (caused by atherosclerosis, arterial or venous thrombosis and embolism, angiospasm)

Diseases of the inner ear (hearing loss due to vascular disease or toxic effects (including iatrogenic), Meniere's disease, tinnitus

Dosage and administration

Intended for intravenous infusion, administered slowly (infusion rate should not exceed 80 drops/min!).

It is forbidden to administer intramuscularly and in a concentrated form intravenously!

To prepare the infusion, you can use saline or infusion solutions containing glucose (Salsol, Ringer, Rindex, Rheomacrodex). The infusion solution with Cavinton® should be used within the first 3 hours after preparation.

Initial daily dose: 20 mg (2 amps) in 500 ml infusion solution for intravenous administration. Depending on the tolerance of the patient, the dose can be increased within 2-3 days, but not more than 1 mg/kg of body weight. The average course of treatment is 10-14 days, the average daily dose is 50 mg with a body weight of 70 kg (5 amps in 500 ml of infusion solution).

Patients with diseases of the liver and kidneys can be prescribed in the same doses.

Side effects

Infrequently ( > 1/1000 <1/100)

feeling hot

Lowering blood pressure

Euphoria

Rarely ( > 1/10000 <1/1000)

Headache, dizziness, drowsiness, restlessness, hemiparesis

Hearing loss, hyperacusis, hypoacusis

Myocardial ischemia/infarction, exertional angina, arrhythmia, bradycardia, tachycardia, extrasystoles, palpitations

Hemorrhage in the anterior chamber of the eye, hypermetropia, decreased visual acuity, myopia

Increased blood pressure, prolongation of the QT interval, depression of the ST segment on the ECG

Hot flashes, asthenia, chest discomfort, injection site thrombosis

Nausea, dry mouth, abdominal discomfort

Erythema, hyperhidrosis, urticaria

Thrombocytopenia, erythrocyte agglutination

Hypercholesterolemia, diabetes mellitus

Increasing the concentration of urea in the blood

Very rarely (<1/10000)

Depression, tremor, loss of consciousness, presyncope

Anorexia, vomiting, hypersecretion of saliva

Heart failure, atrial fibrillation, prolongation of the PR interval on the ECG

Thrombophlebitis

Conjunctival hyperemia, papilledema, diplopia

Noise in ears

Skin itching, dermatitis

Increased activity of lactate dehydrogenase

Contraindications

Hypersensitivity to any component of the drug

Acute cerebral hemorrhage

Severe ischemic heart disease

Severe cardiac arrhythmias

Pregnancy and lactation

Children and adolescents up to 18 years of age

Individuals with hereditary fructose intolerance

Drug Interactions

Cavinton® solution is chemically incompatible with heparin, so their administration in the same syringe is prohibited.

Cavinton® solution is chemically incompatible with infusion solutions containing amino acids, therefore they cannot be used to dilute the Cavinton® injection form.

The simultaneous use of vinpocetine and alpha-methyldopa may cause an increase in the hypotensive effect, therefore, when they are used together, regular monitoring of blood pressure is required.

Despite the lack of data from clinical studies confirming the possibility of interaction, it is recommended to exercise caution when prescribing vinpocetine with drugs that act on the central nervous system, antiarrhythmic drugs and anticoagulants. However, if necessary, the simultaneous use of anticoagulants and Cavinton® is permissible.

special instructions

In the case of increased intracranial pressure, taking antiarrhythmic drugs, cardiac arrhythmias or prolongation of the QT interval, Cavinton® is prescribed after a thorough assessment of the intended benefit and potential risk to the patient.

The presence of the syndrome of prolonged QT interval and the simultaneous use of drugs that cause QT prolongation require periodic monitoring of the electrocardiogram.

Cavinton® injection solution contains sorbitol (160 mg / 2 ml), therefore, if a patient has diabetes, it is necessary to control blood sugar levels.

In case of fructose intolerance or fructose 1,6-diphosphatase deficiency, the drug should be avoided.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

There are no data confirming the adverse effect of vinpocetine on the ability to drive a car and potentially dangerous mechanisms, but given the possibility of developing side effects such as dizziness, drowsiness, care should be taken.

Overdose

Pharmachologic effect:
Cavinton dilates the vessels of the brain, increases blood flow, improves the supply of oxygen to the brain, and also promotes the utilization of glucose. By inhibiting (suppressing) phosphodiesterase, the drug leads to accumulation of cAMP in tissues; reduces aggregation (gluing) of platelets. There is only a slight decrease in systemic arterial pressure.
Vasodilating action Cavinton associated with a direct relaxing (relaxing) effect on smooth muscles. The drug enhances the metabolism (exchange) of norepinephrine and serotonin in brain tissues, reduces pathologically increased blood viscosity, promotes deformability (increase in plasticity) of erythrocytes.

Indications for use

Mode of application

Side effects

Contraindications

Pregnancy

Interaction with other drugs

Overdose

Storage conditions

Release form

Compound

Synonyms

Additionally

Main settings

Cavinton is a drug that improves cerebral circulation and metabolism in the brain. What is this remedy for? Instructions for use recommend taking tablets 5 mg, Forte 10 mg, injections for the treatment of circulatory failure of the brain, vascular eye diseases, hearing loss.

Release form and composition

Produce:

1. Tablets 5 mg.
2. Cavinton forte tablets 10 mg.
3. Concentrate for solution for infusion (injections in ampoules for injection).

The drug contains in its composition the active substance vinpocetine 5 mg. In addition, additional substances are contained. In tablets: talc, silicon dioxide, magnesium stearate, lactose monohydrate and cornstarch. In a concentrate for infusions: tartaric acid, sodium disulfite, injection water, benzyl alcohol, ascorbic acid and sorbitol.

pharmachologic effect

The use of Cavinton helps to increase blood flow, dilate cerebral vessels, improve oxygen supply to the brain, and glucose utilization.

After the drug, a moderate decrease in systemic blood pressure is observed. Vasodilation under the action of the drug is possible due to its relaxing effect on smooth muscles.

Also, the drug enhances the exchange of serotonin, norepinephrine in brain tissues, increases the plasticity of red blood cells, and reduces increased blood viscosity. Vinpocetine is the active ingredient in Cavinton. Instructions for use (price, reviews, analogues of tablets and injections will be discussed in the article below) indicates that the active substance increases cerebral blood flow, reduces the resistance of cerebral vessels without a significant change in systemic circulation indicators (BP, minute volume, heart rate, OPSS).

It does not have a "steal" effect, increases blood supply, primarily in ischemic areas of the brain with low perfusion.

What helps Cavinton?

Indications for the use of the drug include:

• hearing loss of the perceptual type, Meniere's disease, idiopathic tinnitus;
• chronic vascular diseases of the choroid and retina (for example, thrombosis / occlusion / of the central artery or vein of the retina);
• decrease in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency;
• atherosclerosis of cerebral vessels;
• post-traumatic and hypertensive encephalopathy;
• consequences of a stroke.

Why is Cavinton prescribed yet? The agent is indicated for use if the patient has:

• transient ischemic attack;
• vascular dementia;
• vertebrobasilar insufficiency;
• ischemic stroke;
• recovery stage of hemorrhagic stroke.

Instructions for use

Cavinton tablets should be taken 3 times a day, 1-2 tablets. Maintenance dose - 1 tablet three times a day. Treatment with the drug, as a rule, is a long process (from 2 months). When using the medicine according to the indications and in strict accordance with the instructions, the patient's condition usually improves in 1-2 weeks.

Cavinton's solution is used for neurological diseases and acute ischemic focal disorders of cerebral circulation (in the absence of cerebral hemorrhage). The drug is started to be administered with a dosage of 10-20 mg, after dissolving it in 500-1000 ml of isotonic sodium chloride solution.

If there are appropriate indications, Cavinton is administered drip repeatedly (3 times a day), after which it should be switched to tablets.

The drug is also used to prevent children's convulsive syndrome after brain injury. The agent is administered by drip intravenously at a dosage of 8-10 mg / kg of body weight 1 time per day (the drug must first be dissolved in a 5% glucose solution). After 2-3 weeks of such treatment, they switch to the use of tablets inside - 0.5-1 mg / kg of body weight once a day.

Contraindications

• pregnancy;
• lactation period;
• age up to 18 years (due to insufficient data);
• severe arrhythmias;
• known hypersensitivity to vinpocetine;
• acute phase of hemorrhagic stroke;
• severe form of coronary artery disease.

Side effects

• headache;
• dizziness;
• ECG changes (ST depression, prolongation of the QT interval);
• dry mouth;
• nausea;
• sleep disorders (insomnia, increased drowsiness);
• skin allergic reactions;
• general weakness (these symptoms may be manifestations of the underlying disease);
• heartburn;
• tachycardia;
• skin redness;
• change in blood pressure (more often a decrease);
• increased sweating;
• extrasystole (a causal relationship with the drug has not been proven, since in the natural population these symptoms are observed with the same frequency).

Children, during pregnancy and lactation

The drug Cavinton during pregnancy is contraindicated, because. Vinpocetine crosses the placental barrier. At the same time, its level in the placenta and in the blood of the fetus is lower than in the blood of a pregnant woman. At high doses, placental bleeding and spontaneous abortions are possible.

Within an hour, 0.25% of the accepted dose of the drug penetrates into breast milk. When using Cavinton, breastfeeding should be discontinued.

The drug is not prescribed in children under 18 years of age.

special instructions

Cavinton tablets contain lactose. If the patient has hypersensitivity to lactose, it should be borne in mind that one tablet contains 41.5 mg of lactose monohydrate.

The solution for infusion contains sorbitol, therefore, in case of diabetes, the concentration of sugar in the blood should be periodically monitored.

In case of fructose intolerance or fructose 1,6-diphosphatase deficiency, it is not recommended to use vinpocetine in the form of a concentrate.

drug interaction

With simultaneous use, there is no interaction with beta-blockers (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol or hydrochlorothiazide. In rare cases, simultaneous use with alpha-methyldopa is accompanied by some increase in the hypotensive effect; when using this combination, regular monitoring of blood pressure is necessary.

The concentrate for the preparation of a solution for infusion and heparin are chemically incompatible, however, treatment with anticoagulants and vinpocetine can be carried out simultaneously. The concentrate for the preparation of a solution for infusion is incompatible with infusion solutions containing an amino acid.

Cavinton's analogs

Full analogues for the active substance:

1. Vincetin.
2. Vinpoton.
3. Bravinton.
4. Vinpocetine forte.
5. Telektol.
6. Vero-Vinpocetine.
7. Vinpocetine.

Holiday conditions and price

The average price of Cavinton (tablets, No. 50) in Moscow is 199 rubles. In Kyiv, you can buy medicine (tablets, No. 50) for 154 hryvnia, in Kazakhstan - for 2160 tenge. Pharmacies in Minsk offer Cavinton tablets (No. 50) for 12-13 bel. rubles. It is released from pharmacies by prescription.

Post Views: 393

Excipients: colloidal silicon dioxide, magnesium stearate, talc, corn starch, lactose monohydrate.

25 pcs. - blisters (2) - packs of cardboard.

pharmachologic effect

The mechanism of action of vinpocetine consists of several elements: it improves cerebral blood flow and brain metabolism, and has a beneficial effect on the rheological properties of blood.

The neuroprotective effect is realized by reducing the adverse cytotoxic effect of excitatory amino acids. It blocks voltage-dependent Na + and Ca 2+ channels and NMDA and AMPA receptors. Increases the neuroprotective effect of adenosine. Vinpocetine stimulates the metabolism of the brain: it increases the uptake and consumption of oxygen. Increases tolerance to hypoxia; increases the transport of glucose, the only source of energy for brain tissue, through the BBB; shifts glucose metabolism towards the energetically more favorable aerobic pathway. Selectively inhibits Ca 2+ -calmodulin-dependent cGMP-phosphodiesterase; increases the content of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) of the brain, the concentration of ATP and the ratio of ATP / AMP in the brain tissues; enhances metabolism and norepinephrine in the brain, stimulates the noradrenergic neurotransmitter system, and also has an antioxidant effect; as a result of all these effects, vinpocetine has a cerebroprotective effect.

Improves microcirculation in the brain by inhibiting platelet aggregation, reducing pathologically increased blood viscosity, increasing the ability of red blood cells to deform and inhibiting the capture of adenosine; promotes the passage of oxygen into cells by reducing the affinity of red blood cells for it. Selectively increases cerebral blood flow due to an increase in cerebral ejection fraction, a decrease in cerebral vascular resistance without a significant effect on systemic circulatory parameters (BP, cardiac output, heart rate, OPSS); does not have a "steal" effect. Against the background of the use of vinpocetine, the blood supply to damaged (but not yet necrotic) ischemic areas with low perfusion improves ("reverse steal effect").

Pharmacokinetics

Suction

Vinpocetine is rapidly absorbed after oral administration and reaches Cmax in the blood after 1 hour. Absorption occurs mainly in the proximal intestine. It is not metabolized when passing through the intestinal wall. Bioavailability when taken orally - 7%.

Distribution

In preclinical studies of oral administration of radioactively labeled vinpocetine, it was determined in the highest concentrations in the liver and gastrointestinal tract. C max in the tissues is observed 2-4 hours after ingestion. The amount of radioactive isotope in the brain did not exceed that in the blood. Protein binding in the human body - 66%. V d is 246.7 ± 88.5 l, which indicates a significant distribution in tissues. Clearance is 66.7%, which exceeds the plasma volume of the liver (50 l / h), metabolism is predominantly extrahepatic.

With repeated administration at a dose of 5 and 10 mg, the kinetics of vinpocetine is linear. C ss were 1.2±0.27 ng/ml and 2.1±0.33 ng/ml, respectively.

Metabolism

The main metabolite of vinpocetine is apovincamic acid (AVA), whose share in humans is 25-30%. After taking vinpocetine orally, AUC of AVK is 2 times higher than that after intravenous administration. This indicates that VKA is formed during the first pass metabolism of vinpocetine. Other known metabolites are hydroxyvinpocetine, hydroxy-AVK, dihydroxy-AVK-glycinate, as well as their conjugates with glucuronides and/or sulfates.

breeding

T 1/2 in humans is 4.83 ± 1.29 hours. In studies with a radioactive label, the drug was excreted by the kidneys and through the intestines in a ratio of 60:40. In preclinical studies, a significant part of the radioactivity was detected in bile, but no significant enterohepatic circulation was found. In preclinical studies, it was found that unchanged vinpocetine is excreted in a small amount. Apovincaminic acid is excreted by the kidneys by simple glomerular filtration, T 1/2 depends on the dose taken and the route of administration of vinpocetine.

Pharmacokinetics in selected groups of patients

It was found that the pharmacokinetics of vinpocetine in elderly patients does not differ significantly from that in young patients, there is no cumulation of the drug. Therefore, vinpocetine can be prescribed to patients with impaired liver and kidney function for a long time and in normal doses.

Indications

Neurology:

- reduction in the severity of neurological and mental disorders in various forms of cerebral circulatory insufficiency (symptomatic therapy for the consequences of ischemic stroke, vertebrobasilar insufficiency, vascular dementia, cerebral atherosclerosis, post-traumatic and hypertensive encephalopathy);

Ophthalmology:

- chronic vascular diseases of the retina and choroid;

Otorhinolaryngology:

- for the treatment of hearing loss of the perceptual type, Meniere's disease, sensation of tinnitus.

Contraindications

- galactose intolerance, lactase deficiency, glucose-galactose malabsorption;

- pregnancy;

- the period of breastfeeding;

- age up to 18 years (due to insufficient data);

- hypersensitivity to vinpocetine or other components of the drug.

Carefully: long QT interval syndrome, taking drugs that cause a prolongation of the QT interval.

Dosage

Accept inside, after food.

Usually the daily dose is 15-30 mg (5-10 mg 3 times / day).

The initial daily dose is 15 mg. The maximum daily dose is 30 mg.

At kidney and liver diseases the drug is prescribed in the usual dose, the absence of cumulation allows for long courses of treatment.

Side effects

In clinical studies, the most common adverse reactions occurred in the following system organ classes (according to MedDRA classification), which are listed according to the frequency of occurrence: infrequently (from ≥1 / 1000 to<1/100), редко (от ≥1/10 000 до <1/1000); очень редко (<1/10 000).

From the hematopoietic system: rarely - leukopenia, thrombocytopenia; very rarely - anemia, erythrocyte agglutination.

From the immune system: very rarely - hypersensitivity reactions.

From the side of metabolism and nutrition: infrequently - hypercholesterolemia; rarely - loss of appetite, anorexia, diabetes mellitus.

Mental disorders: rarely - insomnia, sleep disturbance, anxiety; very rarely - euphoria, depression.

From the nervous system: infrequently - ; rarely - dizziness, taste disorder, stupor, unilateral paresis, drowsiness, amnesia; very rarely - tremor, spasms.

From the side of the organ of vision: rarely - swelling of the nipple of the optic nerve; very rarely - conjunctival hyperemia.

On the part of the organ of hearing and labyrinth disorders: infrequently - vertigo; rarely - hyperacusis, hypoacusis, tinnitus.

From the side of the cardiovascular system: infrequently - a decrease in blood pressure; rarely - myocardial ischemia / infarction, angina pectoris, bradycardia, tachycardia, extrasystole, palpitations, increased blood pressure, hot flashes, thrombophlebitis; very rarely - blood pressure lability, arrhythmia, atrial fibrillation.

From the digestive system: infrequently - abdominal discomfort, dry mouth, nausea; rarely - epigastric pain, constipation, diarrhea, dyspepsia, vomiting; very rarely - dysphagia, stomatitis.

From the skin and subcutaneous tissues: rarely - erythema, hyperhidrosis, itching, urticaria, rash; very rarely - dermatitis.

General disorders and disorders at the injection site: rarely - asthenia, malaise, feeling of heat; very rarely - a feeling of discomfort in the chest, hypothermia.

Laboratory and instrumental data: rarely - hypertriglyceridemia, ST segment depression on the ECG, decrease / increase in the number of eosinophils, increased activity of liver enzymes; very rarely - a decrease / increase in the number of leukocytes, erythropenia, a decrease in thrombin time, an increase in body weight.

Overdose

There are no data on overdose with vinpocetine. A single dose of 360 mg of vinpocetine did not cause clinically significant reactions, incl. from the cardiovascular system.

Treatment: gastric lavage, activated charcoal, symptomatic therapy.

drug interaction

Interaction is not observed with simultaneous use with (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol, hydrochlorothiazide and imipramine.

The simultaneous use of vinpocetine and alpha-methyldopa sometimes caused some increase in the hypotensive effect, therefore, with this treatment, regular monitoring of blood pressure is required.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when administered simultaneously with drugs that act on the central nervous system, and with antiarrhythmic and anticoagulant drugs.

special instructions

The presence of the syndrome of prolonged QT interval and the use of drugs that cause prolongation of the QT interval requires periodic monitoring of the ECG.

1 tablet of the drug contains 140 mg of lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Influence on the ability to drive vehicles and mechanisms

Data on the effect of vinpocetine on the ability to drive vehicles and work with mechanisms are not available.

Pregnancy and lactation

Pregnancy

Vinpocetine crosses the placental barrier and is therefore contraindicated in pregnancy. At the same time, its concentration in the placenta and in the blood of the fetus is lower than in the blood of a pregnant woman. Teratogenic and embryotoxic effects have not been identified. In animal studies, placental bleeding and spontaneous abortions occurred with the introduction of large doses, probably as a result of increased placental blood flow.

breastfeeding period

Vinpocetine passes into breast milk. In studies using labeled vinpocetine, the radioactivity of breast milk was ten times higher than that of maternal blood. Within 1 hour, 0.25% of the accepted dose of the drug penetrates into breast milk. Since vinpocetine passes into breast milk, and there are no data on the effect of vinpocetine on infants, the use of the drug during breastfeeding is contraindicated.

Application in childhood

Use is contraindicated under the age of 18 years (due to insufficient data).

For impaired renal function

At kidney disease

For impaired liver function

At liver diseases the drug is prescribed in the usual dose.

Terms of dispensing from pharmacies

The drug is dispensed by prescription.

Terms and conditions of storage

The drug should be stored in its original packaging to protect from light, out of reach of children at a temperature not exceeding 30°C. Shelf life - 5 years. Do not use after the expiry date stated on the packaging.

Cavinton 10 is a drug used in the treatment of pathologies of the nervous system, accompanied by circulatory disorders. May cause side effects, so consult your doctor before use.

Cavinton 10 is a drug used in the treatment of pathologies of the nervous system, accompanied by circulatory disorders.

Release form and composition

Pills

The drug is produced in the form of white and round tablets, which are packed in contour cells of 10 pcs. The package contains 9 blisters and instructions.

Each tablet contains:

• vinpocetine (10 mg);
• silicon dioxide, dehydrated;
• magnesium stearate;
• corn starch;
• milk sugar.

Ampoules

The ampoule contains 2 ml of concentrate for solution for infusion.

The composition of the drug includes:

• vinpocetine (10 mg);
• ascorbic acid;
• sodium disulfite;
• benzyl alcohol;
• tartaric acid;
• water for injections.

Ampoules are packed into cardboard cells on 5 pieces. The pack contains 2 blisters, instructions for use and a scarifier.

Pharmacological action of Cavinton 10

Vinpocetine has the following properties:

• Protects brain tissue from damage. Reduces the severity of traumatic cytotoxic reactions supported by stimulating amino acids. Suppresses the activity of calcium and sodium channels.
• Stimulates the protective effect of adenosine. Increases the rate of metabolic processes in the brain tissues, promotes the absorption of more oxygen and glucose. Provides the penetration of glucose through the blood-brain barrier.
• Increases the amount of energy produced as a result of glucose metabolism.
• Stimulates the metabolism of serotonin and norepinephrine in the brain. Has an antioxidant effect.
• Normalizes blood circulation in the cerebral arteries, reduces vascular resistance without affecting the performance of the cardiovascular system (blood pressure, peripheral vascular resistance, heart rate).
• Increases blood supply to areas that have undergone ischemic damage. Increases the resistance of nerve cells to oxygen deficiency.
• Prevents platelet sedimentation, restores blood circulation in peripheral vessels. Eliminates pathological blood viscosity, increases the plasticity of red blood cells, prevents the absorption of adenosine by erythrocytes.

When administered intravenously or orally, the drug is quickly absorbed by the body. The maximum amount of vinpocetine in the blood is detected after 3 hours. Metabolism takes place outside the liver. Most of the active substance leaves the body with urine. 30% of vinpocetine metabolites are excreted in the feces.

Indications for use Cavinton 10

Indications for the use of Cavinton 10 are:

• complications of ischemic stroke;
• recovery after hemorrhagic stroke;
• consequences of transient ischemic attack;
• vascular dementia;
• blockage of the vertebrobasilar arteries;
• atherosclerosis of the arteries of the brain;
• consequences of traumatic brain injury;
• hypertensive encephalopathy;
• chronic vascular insufficiency of the retina and the membrane of the eye;
• perceptual hearing loss;
• tinnitus of unknown etiology;
• Meniere's syndrome.

How to use

Tablets are taken after meals with plenty of water. The recommended daily dose for brain diseases is 30 mg. It is divided into 3 doses. The therapeutic effect occurs approximately 7 days after the start of treatment. To achieve a lasting effect, you need to be treated for at least 3 months.

In case of violation of the functions of the liver and kidneys, dose reduction is not required.

The drug does not have a cumulative effect, so it can be used for long courses. The solution for infusion is injected into a large vein slowly. As a basis, saline or dextrose preparations are used. Begin therapy with the introduction of 25 mg of vinpocetine per day. 2 ampoules are diluted with 500 ml of base. Within 2 weeks, the dose is gradually increased to 50 mg per day.

Side effects of Cavinton 10

Against the background of treatment with Cavinton, the following undesirable consequences may occur:

• violation of the functions of the cardiovascular system (rapid heartbeat, extrasystole, jumps in blood pressure, flushing of the face);
• neurological problems (daytime sleepiness and nighttime insomnia, headache, fainting, general weakness, increased sweating);
• digestive disorders (nausea, vomiting, loose stools, sour belching, dryness of the mucous membranes of the mouth, burning in the esophagus);
• allergic manifestations (skin itching, rashes like urticaria, swelling of the face and larynx, anaphylactic shock).

Contraindications

The drug is not used for:

• acute hemorrhagic stroke;
• severe course of coronary heart disease;
• severe forms of arrhythmia;
• individual intolerance to vinpocetine;
• lactase deficiency;
• glucose-galactose malabsorption.

special instructions

Some body conditions require dose adjustment or withdrawal of the drug.

Use during pregnancy and lactation

Vinpocetine crosses the placental barrier. The concentration of the substance in the blood of the fetus is lower than in the blood of a pregnant woman. With the introduction of high doses of the drug, placental bleeding or spontaneous abortion may occur.

A quarter of the administered dose of vinpocetine is excreted in breast milk. During the treatment period, it is recommended to temporarily suspend HB.

Use in children

The effect of the active substance on the children's body has not been studied, so Cavinton is not prescribed to patients under 18 years of age.

Overdose

The use of large doses of the drug increases the side effects. Treatment involves cleansing the stomach, introducing enterosorbents and maintaining the vital functions of the body.

drug interaction

The drug is compatible with cardiac glycosides, Pindolol, Imipramine.

The use of Cavinton together with Methyldopa contributes to a pronounced decrease in blood pressure, therefore, the administration of drugs is combined with constant control of blood pressure.

With caution MP combined with anticoagulants and antiarrhythmic drugs.

Terms and conditions of storage

Tablets and solution are stored in a dry, dark place at a temperature not exceeding +30°C.

Terms of dispensing from pharmacies

A doctor's prescription is required to purchase the drug.

Price

90 Cavinton tablets cost 760 rubles. 10 ampoules of 5 ml will cost 230 rubles.

Analogues

The following drugs have a similar effect:

• Vinpocetine;
• Korsavin;
• Cavintazole;
• Cavinton Forte;
• Cavinton Comfort.

Reviews of the doctor about the drug Cavinton: indications and contraindications, side effects, analogues

Reviews

Alexander, 30 years old, Anapa: “Due to the spasm of the vessels of the shell of the eye, vision began to deteriorate, headaches appeared. I turned to a neurologist who prescribed Cavinton tablets. I took them 3 times a day, after a week the condition began to improve. He was treated for 3 months, which helped to maintain vision and get rid of headaches. Didn't notice any pronounced side effects. Another positive quality of this medicine is the affordable price.

Maria, 52 years old, Kaluga: “The remedy is effective for many brain diseases. When headaches, fatigue and memory problems appeared, she turned to a neurologist. He conducted an examination, during which a narrowing of the cerebral arteries was revealed. The doctor prescribed Cavinton, which she took for six months. I did not see an immediate effect, but after 2 months the pain began to occur less frequently, and my health improved. Memory has been restored, concentration of attention has increased.

Stepan, 30 years old, Moscow: “Dad takes Cavinton to normalize cerebral circulation. The drug helped to get rid of dizziness, made the signs of varicose veins less pronounced. There were no side effects."

You may be interested in: